Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure

Am J Cardiol. 2003 Sep 1;92(5):628-31. doi: 10.1016/s0002-9149(03)00741-0.

Abstract

Given the limitations of low enrollments, this study suggests that a change of 130% for B-type natiuretic peptide (BNP) and 90% for N-terminal (NT)-proBNP are necessary before results of serially collected data can be considered statistically different. This study also shows that there are important differences in the performance of BNP versus NT-proBNP in monitoring patients with congestive heart failure that need to be further explored.

Publication types

  • Validation Study

MeSH terms

  • Adult
  • Analysis of Variance
  • Atrial Natriuretic Factor / blood*
  • Biomarkers / blood
  • Case-Control Studies
  • Discriminant Analysis
  • Drug Monitoring / methods*
  • Drug Monitoring / standards
  • Female
  • Heart Failure / blood*
  • Heart Failure / classification
  • Heart Failure / diagnosis
  • Heart Failure / drug therapy
  • Humans
  • Immunoassay / methods
  • Immunoassay / standards
  • Male
  • Middle Aged
  • Natriuretic Peptide, Brain
  • Observer Variation
  • Pilot Projects
  • Point-of-Care Systems / standards
  • Protein Precursors / blood*
  • Radioimmunoassay / methods
  • Radioimmunoassay / standards
  • Reference Values
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Time Factors

Substances

  • Biomarkers
  • N-terminal proatrial natriuretic peptide
  • Protein Precursors
  • Natriuretic Peptide, Brain
  • Atrial Natriuretic Factor